• No results found

Schistosomiasis vaccines: where do we stand?

N/A
N/A
Protected

Academic year: 2019

Share "Schistosomiasis vaccines: where do we stand?"

Copied!
15
0
0

Loading.... (view fulltext now)

Full text

Loading

Figure

Table 1 Recent data on Schistosoma mansoni vaccine candidates
Table 1 Recent data on Schistosoma mansoni vaccine candidates (Continued)
Table 2 Recent data on Schistosoma japonicum vaccine candidates
Table 2 Recent data on Schistosoma japonicum vaccine candidates (Continued)
+2

References

Related documents

Urinary liver fatty acid- binding protein: another novel biomarker of acute kidney injury.. Monitoring of Urinary L-Type Fatty Acid- Binding Protein Predicts

A key role of gD homologs in cell entry was es- tablished for all known alphaherpesviruses expressing the protein, including herpes simplex virus 1 (HSV-1), pseudorabies virus

Pseudorabies virus (PrV) pUL34, which exhibits a smooth nu- clear rim staining in infected and transfected cells, is a predicted type II membrane protein (28) with the

In this study, a recombinant JEV vaccine was con- structed by expression of the PrM-E proteins of JEV GI using an attenuated Pseudorabies virus vector (PRV TK − /gE − /LacZ + ).

Comparison of heart- type fatty acid binding protein and sensitive troponin for the diagnosis of early acute myo- cardial infarction. Heart- type fatty acid-binding protein may

Protective immunity induced by the nucleic acid vaccine of fatty acid binding protein of Schistosoma japonicum Chinese strain (SjCFABP) in BALB/c mice. Optimal vaccination against

Sex Differences in Long Chain Fatty Acid Utilization and Fatty Acid Binding Protein Concentration in Rat Liver..

KEYWORDS: Obesity, Waist Circumference, Free Fatty Acid (FFA), Fatty Acid Binding Protein (FABP), Adiponectin, TNF- , Interleukin-6,